MX2022002401A - Productos radiofarmaceuticos, agentes de radioimagenologia,y uso de los mismos. - Google Patents

Productos radiofarmaceuticos, agentes de radioimagenologia,y uso de los mismos.

Info

Publication number
MX2022002401A
MX2022002401A MX2022002401A MX2022002401A MX2022002401A MX 2022002401 A MX2022002401 A MX 2022002401A MX 2022002401 A MX2022002401 A MX 2022002401A MX 2022002401 A MX2022002401 A MX 2022002401A MX 2022002401 A MX2022002401 A MX 2022002401A
Authority
MX
Mexico
Prior art keywords
radiopharmaceuticals
compounds
radioimaging agents
useful
coordinated
Prior art date
Application number
MX2022002401A
Other languages
English (en)
Inventor
Nicholas Alan Zia
Paul Stephen Donnelly
Original Assignee
Clarity Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017902151A external-priority patent/AU2017902151A0/en
Application filed by Clarity Pharmaceuticals Ltd filed Critical Clarity Pharmaceuticals Ltd
Publication of MX2022002401A publication Critical patent/MX2022002401A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
    • C07F1/08—Copper compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Nuclear Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a compuestos que son útiles como productos radiofarmacéuticos y agentes de radioimagenología que tiene un agente quelador de radionúclido. Estos compuestos coordinados son útiles en radioterapia e imagenología de diagnóstico. La invención también se refiere a métodos de diagnosis, prognosis y terapia que utilizan los compuestos no coordinados y radiomarcados de la invención.
MX2022002401A 2017-06-06 2019-12-06 Productos radiofarmaceuticos, agentes de radioimagenologia,y uso de los mismos. MX2022002401A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2017902151A AU2017902151A0 (en) 2017-06-06 Radiopharmaceuticals, radioimaging agents, and uses thereof

Publications (1)

Publication Number Publication Date
MX2022002401A true MX2022002401A (es) 2022-03-22

Family

ID=64565650

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019014758A MX2019014758A (es) 2017-06-06 2018-06-05 Productos radiofarmaceuticos, agentes de radioimagenologia, y uso de los mismos.
MX2022002401A MX2022002401A (es) 2017-06-06 2019-12-06 Productos radiofarmaceuticos, agentes de radioimagenologia,y uso de los mismos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019014758A MX2019014758A (es) 2017-06-06 2018-06-05 Productos radiofarmaceuticos, agentes de radioimagenologia, y uso de los mismos.

Country Status (15)

Country Link
US (4) US10975089B2 (es)
EP (2) EP3634965B1 (es)
JP (2) JP7144451B2 (es)
KR (1) KR102644075B1 (es)
CN (2) CN110914274B (es)
AU (1) AU2018280338B2 (es)
BR (1) BR112019025881A2 (es)
CA (1) CA3066525A1 (es)
DK (1) DK3634965T3 (es)
ES (1) ES2943458T3 (es)
FI (1) FI3634965T3 (es)
MX (2) MX2019014758A (es)
PL (1) PL3634965T3 (es)
PT (1) PT3634965T (es)
WO (1) WO2018223180A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201504064D0 (en) 2015-03-10 2015-04-22 Accretion Biotechnology Ltd Method and kits for preparing radionuclide complexes
CN112423744A (zh) 2018-04-11 2021-02-26 透明医药有限公司 用于放射疗法和诊断成像的制剂和试剂盒
CN114423421A (zh) * 2019-05-24 2022-04-29 透明医药有限公司 Psma显像剂的制剂
WO2020252598A1 (en) * 2019-06-21 2020-12-24 Provincial Health Services Authority Radiolabeled compounds targeting the prostate-specific membrane antigen
WO2021087568A1 (en) * 2019-11-08 2021-05-14 The University Of Queensland Radiolabelled targeting ligands
JP2023523226A (ja) * 2020-04-29 2023-06-02 ノバルティス アーゲー Ｐｓｍａ結合リガンドを放射標識するための方法及びそのキット
US20240050600A1 (en) * 2020-08-14 2024-02-15 Clarity Pharmaceuticals Ltd Radiopharmaceuticals, uses thereof, and methods for the production thereof
US20240018099A1 (en) * 2020-11-19 2024-01-18 Novartis Ag Synthesis of prostate specific membrane antigen (psma) ligands
WO2022123462A1 (en) * 2020-12-09 2022-06-16 3B Pharmaceuticals Gmbh Radiolabelled prostate specific membrane antigen (psma) inhibitors and use thereof
US20240082435A1 (en) * 2021-02-26 2024-03-14 Telix International (Innovations) Pty Ltd Solid phase synthesis of glutamate-urea-lysine derived (GUL derived) prostate-specific membrane antigen (PSMA) targeting conjugates and their use as precursors for therapeutic and/or diagnostic agents
EP4387944A1 (en) * 2021-08-17 2024-06-26 Clarity Pharmaceuticals Ltd Radiopharmaceuticals, methods for the production thereof, and uses in treatment, diagnosis and imaging diseases
KR20240115844A (ko) * 2021-11-24 2024-07-26 클라리티 파마슈티컬스 리미티드 암의 치료용 화합물 및 이의 조성물
WO2024031153A1 (en) * 2022-08-11 2024-02-15 Clarity Pharmaceuticals Limited Dimeric radiopharmaceuticals, compositions thereof and uses thereof
US20240189460A1 (en) 2022-09-23 2024-06-13 Nuclidium Ag High purity copper radiopharmaceutical compositions and diagnostic and therapeutic uses thereof
WO2024168386A1 (en) * 2023-02-14 2024-08-22 Clarity Pharmaceuticals Limited Methods for the detection and diagnosis of cancers associated with overexpression of a psma receptor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP803899A0 (en) * 1999-01-05 1999-01-28 Australian National University, The Cryptate compounds and methods for diagnosis and therapy.
US8097237B2 (en) * 2005-08-23 2012-01-17 Stc.Unm Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma
ES2712881T3 (es) * 2008-12-02 2019-05-16 Univ Melbourne Conjugados macrocíclicos que contienen nitrógeno como radiofármacos
JP6207504B2 (ja) * 2011-07-07 2017-10-04 オーストラリアン ニュークリア サイエンス アンド テクノロジー オーガニゼーション クリプテート化合物
US9457107B2 (en) * 2011-12-06 2016-10-04 The University Of Melbourne Cage amine ligands for metallo-radiopharmaceuticals
CN103638536B (zh) * 2013-12-11 2016-06-22 东南大学 一种分子探针及其制备方法和应用

Also Published As

Publication number Publication date
US20220041608A1 (en) 2022-02-10
JP7144451B2 (ja) 2022-09-29
US20230382918A1 (en) 2023-11-30
PL3634965T3 (pl) 2023-08-07
EP4209495A1 (en) 2023-07-12
PT3634965T (pt) 2023-04-20
CN115322244A (zh) 2022-11-11
EP3634965A4 (en) 2021-03-03
BR112019025881A2 (pt) 2020-06-30
KR20200011950A (ko) 2020-02-04
ES2943458T3 (es) 2023-06-13
RU2019144070A3 (es) 2021-09-28
DK3634965T3 (da) 2023-05-01
WO2018223180A1 (en) 2018-12-13
AU2018280338B2 (en) 2021-07-15
JP7506121B2 (ja) 2024-06-25
JP2020522478A (ja) 2020-07-30
EP3634965A1 (en) 2020-04-15
RU2019144070A (ru) 2021-07-12
CN110914274B (zh) 2022-08-26
MX2019014758A (es) 2022-02-28
US11970503B2 (en) 2024-04-30
US20220315596A1 (en) 2022-10-06
US20200095257A1 (en) 2020-03-26
EP3634965B1 (en) 2023-02-22
US10975089B2 (en) 2021-04-13
AU2018280338A1 (en) 2019-12-19
KR102644075B1 (ko) 2024-03-07
JP2022184952A (ja) 2022-12-13
CN110914274A (zh) 2020-03-24
FI3634965T3 (fi) 2023-05-04
CA3066525A1 (en) 2018-12-13
US11384088B2 (en) 2022-07-12

Similar Documents

Publication Publication Date Title
MX2022002401A (es) Productos radiofarmaceuticos, agentes de radioimagenologia,y uso de los mismos.
ZA201906832B (en) Novel psma-binding agents and uses thereof
MX2021008976A (es) Inhibidores marcados de antigeno prostatico especifico de membrama (psma), su uso como agentes formadores de imagenes y agentes farmaceuticos para el tratamiento de cancer de prostata.
PH12015501744A1 (en) Therapeutic and diagnostic target for cancer comprising dll3 binding reagents
GEP20207151B (en) Agents, Uses and Methods for the Treatment of Synucleinopathy
MX2022014611A (es) Compuestos para tomografia por emision de positrones.
SA518391121B1 (ar) 18f مثبطات موسومة بواسطة (psma) في مستضد الغشاء الخاص بالبروستاتا واستخدامها كعوامل تصوير تشخيصي لحالات سرطان البروستاتا
MX2017003886A (es) Conjugado radiofarmaceutico de un metabolito y un agente epr para tratar celulas tumorales.
MX2015008993A (es) Radiofarmaceuticos y agentes de radio-formacion de imagen a base de triazina.
MX2023005053A (es) Ligandos de psma para la formacion de imagenes y endorradioterapia.
EA201891444A1 (ru) ЛИГАНДЫ mGluR2/3 ДЛЯ PET, МЕЧЕННЫЕ РАДИОАКТИВНЫМИ ИЗОТОПАМИ
MX2015012528A (es) Inhibidores macrociclicos de cinasa inducibles por sal.
MX2018000239A (es) Bifosfonatos de hbed, sus conjugados radio metalicos y su uso como agentes teranosticos.
JP2014508784A5 (es)
MX2021014292A (es) Formulaciones de agentes de imagen de psma.
MX2012012479A (es) Metodos, composiciones y accesorios para proporcionar un tratamiento terapeutico.
MX2017010625A (es) Alfa-1-microglobulina para usarse en la proteccion de los riñones en terapia con radionucleidos.
WO2015042446A3 (en) Compositions and methods for the analysis of radiosensitivity
WO2019126594A3 (en) Antibodies to centrin-1, methods of making, and uses thereof
PT3643707T (pt) Composto marcado com 18f para o diagnóstico do cancro da próstata e a respetiva utilização
NZ758917A (en) Compounds for positron emission tomography